HomeCompareSFT vs MRK

SFT vs MRK: Dividend Comparison 2026

SFT yields 1174.40% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SFT wins by $77588879.98M in total portfolio value
10 years
SFT
SFT
● Live price
1174.40%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77588880.04M
Annual income
$66,457,117,586,405.53
Full SFT calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — SFT vs MRK

📍 SFT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSFTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SFT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SFT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SFT
Annual income on $10K today (after 15% tax)
$99,823.84/yr
After 10yr DRIP, annual income (after tax)
$56,488,549,948,444.70/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, SFT beats the other by $56,488,549,939,847.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SFT + MRK for your $10,000?

SFT: 50%MRK: 50%
100% MRK50/50100% SFT
Portfolio after 10yr
$38794440.05M
Annual income
$33,228,558,798,259.66/yr
Blended yield
85.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SFT
Analyst Ratings
9
Hold
1
Sell
Consensus: Hold
Altman Z
-10.3
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SFT buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSFTMRK
Forward yield1174.40%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$77588880.04M$57.7K
Annual income after 10y$66,457,117,586,405.53$10,113.78
Total dividends collected$76756141.26M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: SFT vs MRK ($10,000, DRIP)

YearSFT PortfolioSFT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$128,140$117,439.81$11,213$373.04+$116.9KSFT
2$1,543,532$1,406,422.01$12,667$512.06+$1.53MSFT
3$17,484,583$15,833,003.89$14,439$708.14+$17.47MSFT
4$186,325,976$167,617,472.01$16,640$988.16+$186.31MSFT
5$1,868,742,776$1,669,373,982.36$19,432$1,394.07+$1868.72MSFT
6$17,647,091,734$15,647,536,963.09$23,057$1,992.90+$17647.07MSFT
7$156,979,890,793$138,097,502,638.19$27,889$2,894.79+$156979.86MSFT
8$1,316,050,532,150$1,148,082,049,001.50$34,518$4,286.29+$1316050.50MSFT
9$10,403,516,309,906$8,995,342,240,505.43$43,912$6,494.35+$10403516.27MSFT
10$77,588,880,038,005$66,457,117,586,405.53$57,714$10,113.78+$77588879.98MSFT

SFT vs MRK: Complete Analysis 2026

SFTStock

Shift Technologies, Inc., together with its subsidiaries, provides an ecommerce platform for buying and selling used cars. The company operates in two segments, Retail and Wholesale. It engages in the retail sale of used vehicles through its platform that enables mobile digital transaction, such as at-home car searching, scheduling an on-demand test drive, and purchasing at home or at the preferred site of a test drive, as well as provides financing and services. The company also provides value-added products, such as vehicle service contracts, guaranteed asset protection waiver coverage, wheel and tire coverage, prepaid maintenance plans, and appearance protection plans. In addition, it is involved in the sale of used vehicles through wholesale auctions or directly to a wholesaler. The company was incorporated in 2013 and is headquartered in San Francisco, California.

Full SFT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SFT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SFT vs SCHDSFT vs JEPISFT vs OSFT vs KOSFT vs MAINSFT vs JNJSFT vs ABBVSFT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.